Best Practice and Research. Clinical Haematology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Transplantation without pretransplant therapy: Is this a possibility? Insights into providing transplantation at diagnosis for patients with acute leukemia
Publication date: Available online 18 October 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Nelson J. ChaoAbstractAllogeneic hematopoietic stem cell transplantation (HSCT) has the potential for providing a cure for several hematologic malignancies. Although in most circumstances, allogeneic HSCT is preceded by disease-directed or cytoreductive therapy, it is unclear if these toxic conditioning regimens can be circumvented. This review summarizes evidence that will provide insights into factors that influence outcomes in allogeneic HSCT and whether this curative therapy could be used right at diagnosis...
Source: Best Practice and Research Clinical Haematology - October 18, 2019 Category: Hematology Source Type: research

What do functional genomics tell us about pathogenesis of AML?
Publication date: Available online 18 October 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Jeffrey W. Tyner, Daniel Bottomly, Beth Wilmot, Shannon McWeeneyAbstractWhile molecular genetic abnormalities can tell us much about the pathogenesis of acute myeloid leukemia (AML), these molecular genetics do not always explain drug resistance or sensitivity, leaving room for other mechanisms of tumor pathogenesis outside of genetic events. The Beat AML 1.0 project was a multicenter project to sequence and functionally query AML samples against over 120 drugs. The results have helped form disease models on ho...
Source: Best Practice and Research Clinical Haematology - October 18, 2019 Category: Hematology Source Type: research

Will new agents impact survival in AML?
Publication date: Available online 18 October 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Jacob M. RoweAbstractIn recent years, several drugs—including midostaurin, gilteritinib, and gemtuzumab ozogamicin, to name a few—have been approved or reapproved in the United States to treat patients with acute myeloid leukemia (AML). Yet survival rates for younger patients had improved with chemotherapy alone even before the approvals of these new agents. This begs the question whether the new therapies will actually have a positive impact on survival. The 5-year survival rate for older patients has also...
Source: Best Practice and Research Clinical Haematology - October 18, 2019 Category: Hematology Source Type: research

ftableWhich novel agents hold the greatest promise in AML?
Publication date: Available online 18 October 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Courtney DiNardoAbstractThe therapeutic landscape for acute myeloid leukemia (AML) has changed dramatically with the approval of targeted agents, including venetoclax, midostaurin, gilteritinib, ivosidenib, and enasidenib, among others. However, older patients with AML continue to experience poorer outcomes and are in ongoing need of more effective and less toxic regimens. This review examines the efficacy of novel therapeutics and promising combination approaches to further improve outcomes in the treatment of...
Source: Best Practice and Research Clinical Haematology - October 18, 2019 Category: Hematology Source Type: research

Can we selectively target AML stem cells?
Publication date: Available online 18 October 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Craig T. JordanAbstractDe novo acute myeloid leukemia (AML) leukemia stem cell (LSC) populations are uniquely dependent on amino acid metabolism to drive the TCA cycle and oxidative phosphorylation. Oxidative phosphorylation can be selectively downregulated in de novo AML LSC populations by perturbing amino acid metabolism via BCL2 inhibition with venetoclax. While venetoclax-based therapies have shown high response rates, not all patients achieve remission. It may be possible to prospectively identify the pati...
Source: Best Practice and Research Clinical Haematology - October 18, 2019 Category: Hematology Source Type: research

MAGIC biomarkers of acute graft-versus-host disease: biology and clinical application
Publication date: Available online 18 October 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Hrishikesh K. Srinagesh, James L.M. FerraraAbstractAcute graft-versus-host disease (GVHD) is the major complication of allogeneic hematopoietic cell transplantation and is the primary cause of early non-relapse mortality (NRM) after transplant. GVHD of the gastrointestinal (GI) tract fuels the systemic inflammatory reaction and consequently is the principal driver of mortality. Recently, the MAGIC algorithm probability (MAP) that is computed from two biomarkers of GI GVHD has been validated to accurately predic...
Source: Best Practice and Research Clinical Haematology - October 18, 2019 Category: Hematology Source Type: research

Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies
Publication date: Available online 18 October 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Mathew L. Cooper, John F. DiPersioAbstractAt present, the only curative therapy for patients with T-cell malignancies is allogeneic stem cell transplant, which has associated risks and toxicities. Novel agents have been tried in relapsed T-cell acute lymphoblastic leukemia (T-ALL), but only one, with 20%-30% complete remission rates, has been approved by the US Food and Drug Administration. T-ALL is a heterogeneous disease, but it has universal overexpression of CD7 as well as several other T-cell markers, such...
Source: Best Practice and Research Clinical Haematology - October 18, 2019 Category: Hematology Source Type: research

How close are we to CAR T-cell therapy for AML?
Discussion and clinical examples of potential solutions to creating a safe and effective CAR T cell for AML include: (1) Decreasing the potency or activity of CAR T cells; (2) Using transient or depleted CAR T cells as part of pre-transplant conditioning; and (3) Using a gene-edited allogeneic donor hematopoietic stem cell transplant in order to allow safe and protracted anti-AML CAR T-cell function. (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - October 18, 2019 Category: Hematology Source Type: research

What have we learned from transplanting older patients?
Publication date: Available online 18 October 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Indumathy Varadarajan, Karen K. BallenAbstractAggressive curative therapies have now been extended to patients older than 65 years, a fast-growing segment of the population. As the number of allogeneic transplants in patients older than age 65 is increasing, attention is now focused on improving outcomes in this group. This paper discusses important aspects of allogeneic transplant in the older patient, focusing on donor and patient selection, choice of conditioning regimen and graft source, and the importance ...
Source: Best Practice and Research Clinical Haematology - October 18, 2019 Category: Hematology Source Type: research

Does early diagnosis and treatment of myelodysplastic syndromes make a difference?
Publication date: Available online 18 October 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): David P. SteensmaAbstractPatients diagnosed with myelodysplastic syndromes (MDS) often ask their physicians whether earlier detection of disease or more prompt initiation of treatment might have resulted in a better outcome. The concept of starting therapy at an early point in the disease process when the clonal burden of abnormal hematopoietic stem cells may be lower and somatic mutational complexity less, and therefore treatment more likely to be effective, is attractive. However, at present there is no evide...
Source: Best Practice and Research Clinical Haematology - October 18, 2019 Category: Hematology Source Type: research

How advanced are we in targeting novel subtypes of ALL?
Publication date: Available online 18 October 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Charles G. MullighanAbstractDespite high cure rates in children, acute lymphoblastic leukemia (ALL) remains a leading cause of cancer death in the young, and the likelihood of treatment failure increases with age. With the exception of tyrosine kinase inhibitors, there have been few advances in repurposing or developing new therapeutic approaches tailored to vulnerabilities of ALL subtypes or individual cases. Large-scale genome profiling studies conducted over the last decade promise to improve ALL outcomes by...
Source: Best Practice and Research Clinical Haematology - October 18, 2019 Category: Hematology Source Type: research

Maintenance therapy after allogeneic hematopoietic cell transplantation for acute myeloid leukemia
Publication date: Available online 18 October 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Frederick R. AppelbaumAbstractWith improvements in the safety of allogeneic hematopoietic cell transplantation, disease recurrence following the procedure is now the most frequent reason for treatment failure. Administration of maintenance therapy after transplantation is one way to try and prevent recurrence. This paper provides a brief review of the topic. (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - October 18, 2019 Category: Hematology Source Type: research

Can Ph-like ALL be effectively targeted?
Publication date: Available online 18 October 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Luke Maese, Elizabeth A. RaetzAbstractPhiladelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a high-risk subset of B-cell ALL with a spectrum of underlying genetic alterations that activate kinase or cytokine receptor signaling. Ph-like ALL occurs at all ages but is most common in adolescents and young adults and is postulated to be a factor in the inferior outcomes in this age group. Ph-like ALL confers a poor prognosis with conventional chemotherapy and the pediatric and adult oncology com...
Source: Best Practice and Research Clinical Haematology - October 18, 2019 Category: Hematology Source Type: research

Editorial Board / Aims & Scope
Publication date: September 2019Source: Best Practice & Research Clinical Haematology, Volume 32, Issue 3Author(s): (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - October 2, 2019 Category: Hematology Source Type: research

Index
Publication date: September 2019Source: Best Practice & Research Clinical Haematology, Volume 32, Issue 3Author(s): (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - October 2, 2019 Category: Hematology Source Type: research